套细胞淋巴瘤首次缓解后自体造血干细胞移植长期生存:III期随机试验事后分析
该事后分析基于一项开放标签、多中心、随机III期试验,纳入174例对诱导治疗有反应的初治III-IV期套细胞淋巴瘤患者,中位随访14年。未用利妥昔单抗者获益显著,用利妥昔单抗者获益减弱。
要点
- 自体HSCT较干扰素α维持显著改善首次缓解套细胞淋巴瘤的PFS和OS。
- 未接受利妥昔单抗者HSCT获益显著,接受利妥昔单抗者获益减弱。
- 免疫化疗时代需重新评估自体HSCT在套细胞淋巴瘤中的地位。
核心结论
- 结果证实自体HSCT在利妥昔单抗前时代对套细胞淋巴瘤的长期疗效。
- 免疫化疗后疗效可能减弱,支持在抗体维持、大剂量阿糖胞苷和靶向治疗改变标准治疗背景下重新评估自体HSCT。
研究设计与样本
- 开放标签、多中心、随机III期试验的事后长期分析,在6个欧洲国家121家医院或诊所进行。
- 269例18-65岁、初治III-IV期、ECOG 0-2的套细胞淋巴瘤患者随机1:1接受自体HSCT或干扰素α维持。
- 意向治疗人群为174例对诱导治疗有反应者(自体HSCT组93例[53%],干扰素α组81例[47%]),中位随访14年(IQR 10-16)。
关键数值与推荐
- 中位年龄55岁(IQR 47-60),R-CHOP用于174例中的68例(39%)。
- PFS和OS的HR均按MIPI数值评分校正,总组还按利妥昔单抗使用校正。
临床怎么用
- 对适合的初治晚期套细胞淋巴瘤患者,首次缓解后自体HSCT仍是利妥昔单抗前时代证据支持的标准选择。
- 在已接受利妥昔单抗免疫化疗的患者中,自体HSCT的长期获益可能减弱,决策需结合当前靶向治疗和维持治疗进展个体化评估。
局限性
- 为事后分析,意向治疗人群仅限对诱导治疗有反应者。
- 试验开始于预注册实施前,因此未注册。
- 利妥昔单抗亚组样本量有限,HR置信区间宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autologous haematopoietic stem-cell transplantation (HSCT) in first remission is the current standard treatment in fit patients with mantle cell lymphoma. In this long-term follow-up study, we aimed to evaluate the efficacy of autologous HSCT versus interferon alfa maintenance after chemotherapy without or with rituximab in patients with primary advanced-stage mantle cell lymphoma. METHODS: We did a post-hoc, long-term analysis of an open-label, multicentre, randomised, phase 3 trial done in 121 participating hospitals or practices across six European countries. Patients who were aged 18-65 years with previously untreated stage III-IV mantle cell lymphoma and an ECOG performance score of 0-2 were eligible for participation. Patients were randomly assigned (1:1) to receive either myeloablative radiochemotherapy (fractionated total body irradiation with 12 Gy/day 6-4 days before autologous HSCT and cyclophosphamide 60 mg/kg per day intravenously 3-2 days before autologous HSCT) followed by autologous HSCT (the autologous HSCT group) or interferon alfa maintenance (the interferon alfa maintenance group; 6 × 106 IU three times a week subcutaneously until progression) after completion of CHOP-like induction therapy (cyclophosphamide 750 mg/m2 intravenously on day 1, doxorubicin 50 mg/m2 intravenously on day 1, vincristine 1·4 mg/m2 [maximum 2 mg] intravenously on day 1, and prednisone 100 mg/m2 orally on days 1-5; repeated every 21 days for up to 6 cycles) without or with rituximab (375 mg/m2 intravenously on day 0 or 1 of each cycle; R-CHOP). The primary outcome was progression-free survival from end of induction until progression or death among patients who had a remission and the secondary outcome was overall survival from the end of induction until death from any cause. We did comparisons of progression-free survival and overall survival according to the intention-to-treat principle between both groups among responding patients and explored efficacy in subgroups according to induction treatment without or with rituximab. Hazard ratios (HRs) were adjusted for the mantle cell lymphoma international prognostic index (MIPI) numerical score, and in the total group also for rituximab use (adjusted HR [aHR]). This trial was started before preregistration was implemented and is therefore not registered, recruitment is closed, and this is the final evaluation. FINDINGS: Between Sept 30, 1996, and July 1, 2004, 269 patients were randomly assigned to receive either autologous HSCT or interferon alfa maintenance therapy. The median follow-up was 14 years (IQR 10-16), with the intention-to-treat population consisting of 174 patients (93 [53%] in the autologous HSCT group and 81 [47%] in the interferon alfa maintenance group) who responded to induction therapy. The median age was 55 years (IQR 47-60), and R-CHOP was used in 68 (39%) of 174 patients. The median progression-free survival was 3·3 years (95% CI 2·5-4·3) in the autologous HSCT group versus 1·5 years (1·2-2·0) in the interferon alfa maintenance group (log-rank p<0·0001; aHR 0·50 [95% CI 0·36-0·69]). The median overall survival was 7·5 years (95% CI 5·7-12·0) in the autologous HSCT group versus 4·8 years (4·0-6·6) in the interferon alfa maintenance group (log-rank p=0·019; aHR 0·66 [95% CI 0·46-0·95]). For patients treated without rituximab, the progression-free survival adjusted HR for autologous HSCT versus interferon alfa was 0·40 (0·26-0·61), in comparison to 0·72 (0·42-1·24) for patients treated with rituximab. For overall survival, the adjusted hazard ratio for HSCT versus interferon alfa was 0·52 (0·33-0·82) without rituximab and 1·05 (0·55-1·99) for patients who received rituximab. INTERPRETATION: Our results confirm the long-term efficacy of autologous HSCT to treat mantle cell lymphoma established in the pre-rituximab era. The suggested reduced efficacy after immunochemotherapy supports the need for its re-evaluation now that antibody maintenance, high-dose cytarabine, and targeted treatments have changed the standard of care for patients with mantle cell lymphoma. FUNDING: Deutsche Krebshilfe, the European Community, and the Bundesministerium für Bildung und Forschung, Kompetenznetz Maligne Lymphome.
引用
- Zoellner AK, Unterhalt M, Stilgenbauer S, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021. PMID: 34450102. doi:10.1016/S2352-3026(21)00195-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。